Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to reveal the clinicopathological characteristics and prognostic implications associated with fibroblast growth factor receptor 1 (FGFR1) amplification in colorectal cancers (CRCs). Materials and Methods We measured the copy number of FGFR1 by droplet digital polymerase chain reaction (ddPCR), and analyzed the FGFR1 expression by immunohistochemistry, in 764 surgically resected CRCs (SNUH2007 dataset, 384 CRCs; SNUH Folfox dataset, 380 CRCs). Results CRCs with ! 3.3 copies of the FGFR1 gene were classified as FGFR1 amplified. FGFR1 amplification was found in 10 of the 384 CRCs (2.6%) in the SNUH2007 dataset, and in 28 of the 380 CRCs (7.4%) in the SNUH Folfox dataset. In the SNUH2007 dataset, there was no association between the FGFR1 copy number status and sex, gross appearance, stage, or differentiation. High FGFR1 expression was associated with female sex and KRASmutation. At the molecular level, FGFR1 amplification was mutually exclusive with BRAF mutation, microsatellite instability, and MLH1 methylation, in both SNUH2007 and SNUH Folfox datasets. Survival analysis revealed that FGFR1 amplification was associated with significantly worse clinical outcome compared with no FGFR1 amplification, in both SNUH2007 and SNUH Folfox datasets. Within the SNUH2007 dataset, CRC patients with high FGFR1 expression had an inferior progression-free survival compared with those with low FGFR1 expression. The FGFR inhibitor, PD173074, repressed the proliferation of a CRC cell line overexpressing FGFR1, but not of cells with FGFR1 amplification. Conclusion FGFR1 amplification measured by ddPCR can be a prognostic indicator of poor clinical outcome in patients with CRCs.
Abstract
Purpose The purpose of this study was to reveal the clinicopathological characteristics and prognostic implications associated with fibroblast growth factor receptor 1 (FGFR1) amplification in colorectal cancers (CRCs). Materials and Methods We measured the copy number of FGFR1 by droplet digital polymerase chain reaction (ddPCR), and analyzed the FGFR1 expression by immunohistochemistry, in 764 surgically resected CRCs (SNUH2007 dataset, 384 CRCs; SNUH Folfox dataset, 380 CRCs). Results CRCs with ! 3.3 copies of the FGFR1 gene were classified as FGFR1 amplified. FGFR1 amplification was found in 10 of the 384 CRCs (2.6%) in the SNUH2007 dataset, and in 28 of the 380 CRCs (7.4%) in the SNUH Folfox dataset. In the SNUH2007 dataset, there was no association between the FGFR1 copy number status and sex, gross appearance, stage, or differentiation. High FGFR1 expression was associated with female sex and KRASmutation. At the molecular level, FGFR1 amplification was mutually exclusive with BRAF mutation, microsatellite instability, and MLH1 methylation, in both SNUH2007 and SNUH Folfox datasets. Survival analysis revealed that FGFR1 amplification was associated with significantly worse clinical outcome compared with no FGFR1 amplification, in both SNUH2007 and SNUH Folfox datasets. Within the SNUH2007 dataset, CRC patients with high FGFR1 expression had an inferior progression-free survival compared with those with low FGFR1 expression. The FGFR inhibitor, PD173074, repressed the proliferation of a CRC cell line overexpressing FGFR1, but not of cells with FGFR1 amplification. Conclusion FGFR1 amplification measured by ddPCR can be a prognostic indicator of poor clinical outcome in patients with CRCs.
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
- Fearon ER, "A genetic model for colorectal tumorigenesis", Cell, 61, pp.759~767 (1990)
- Ciriello G, "Emerging landscape of oncogenic signatures across human cancers", Nat Genet, 45, pp.1127~1133 (2013)
- Dienstmann R, "Genomic aberrations in the FGFR pathway : opportunities for targeted therapies in solid tumors", Ann Oncol, 25, pp.552~563 (2014)
- Kim HR, "Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer", J Clin Oncol, 31, pp.731~737 (2013)
- Kim HS, "Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma", Oncotarget, 6, pp.2562~2572 (2015)
- Elbauomy Elsheikh S, "FGFR1 amplification in breast carcinomas : a chromogenic in situ hybridisation analysis", Breast Cancer Res, 9, pp.R23~ (2007)
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
- Fritzsche FR, "Determination of the Her-2", neu gene amplification status in cytologic breast cancer specimens using automated silverenhanced in-situ hybridization(SISH), 2010, pp.34, 1180~1185
- Yoo SB, "Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in nonsmall-cell lung carcinomas : a comparison with fluorescence in situ hybridization study", Lung Cancer, 67, pp.301~305 (2010)
- Huggett JF, "Considerations for digital PCR as an accurate molecular diagnostic tool", Clin Chem, 61, pp.79~88 (2015)
- Goke F, "Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer", Digestion, 88, pp.172~181 (2013)
- Bae JM, "Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system", Br J Cancer, 116, pp.1012~1020 (2017)
- Kinugasa H, "Droplet digital PCR measurement of HER2 in patients with gastric cancer", Br J Cancer, 112, pp.1652~1655 (2015)
- Ribic CM, "Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer", N Engl J Med, 349, pp.247~257 (2003)
- Yao TJ, "AZD-4547exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor(FGFR)-expressing colorectal cancer cells", Tumour Biol, 36, pp.5641~5648 (2015)
- Liu J, "An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics", Cell, 173, pp.400~416.e11 (2018)
- Liu Y, "Comparative molecular analysis of gastrointestinal adenocarcinomas", Cancer Cell, 33, pp.721~735.e8 (2018)
- Kwak Y, "Fibroblast growth factor receptor 1 gene copy number and mRNA expression in primary colorectal cancer and its clinicopathologic correlation", Pathobiology, 82, pp.76~83 (2015)
- Turner N, "FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer", Cancer Res, 70, pp.2085~2094 (2010)
- Hindson BJ, "High-throughput droplet digital PCR system for absolute quantitation of DNA copy number", Anal Chem, 83, pp.8604~8610 (2011)
- Zhu Y, "Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples", Exp Mol Pathol, 100, pp.287~293 (2016)
- Koole K, "FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma", Clin Cancer Res, 22, pp.3884~3893 (2016)
- Yang X, "Gene body methylation can alter gene expression and is a therapeutic target in cancer", Cancer Cell, 26, pp.577~590 (2014)
- Sato T, "Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer", Oncol Rep, 21, pp.211~216 (2009)
- Shaw AT, "Tyrosine kinase gene rearrangements in epithelial malignancies", Nat Rev Cancer, 13, pp.772~787 (2013)
- Paik PK, "A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers : preliminary antitumor activity and pharmacodynamic data", J Clin Oncol, 32(15 Suppl), pp.8035~ (2014)
- Weiss J, "Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer", Sci Transl Med, 2, pp.62ra93~ (2010)